FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...

Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...

Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for ...

How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing ...

AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.

MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal ...

Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf ...

Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in ...

AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.

A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring ...

Akeso's ivonescimab met overall survival endpoint in Phase III trial for EGFR-TKI-resistant NSCLC, with consistent results ...

Tezspire hits both primary endpoints in Phase 3 eosinophilic esophagitis trial, addressing histologic remission and dysphagia ...